UCSF evaluates new device to treat heart failure

March 17, 2001

UCSF researchers have begun clinical trials on a new device to treat patients with heart failure -- a progressive cardiovascular disease affecting more than five million Americans.

Investigators at UCSF implanted the first such device in the United States in 1996 and continue to lead research and development of implantable technology to fix hearts in which the lower chambers, the ventricles, don't pump together, as they do in a healthy heart.

The pacemaker-like device, works to resynchronize the left and right ventricles. The result is that the heart's pumping ability is stronger, according to Leslie Saxon, MD, and Teresa De Marco, MD, UCSF associate professors of medicine and co-investigators on a nationwide, randomized study to evaluate the device.

Preliminary data indicate that this technology can not only resynchronize the heart, but also support slow heart beats, detect abnormal beats before they become a significant problem, help heart failure physicians manage medications, and even prevent sudden death, said Saxon, who will present findings at the American College of Cardiology meeting March 18-21, 2001 in Orlando, Florida.

In an outpatient procedure, the device is placed under the skin near the shoulder. Physicians insert three electricity-delivering wires into a vein near the collarbone. Two wires are guided to the right ventricle of the heart, just as in a pacemaker implantation. The third wire, the new innovation, goes to the left ventricle and helps the two ventricles beat together. Heart failure is different from a heart attack. It occurs in people who may have survived a heart attack or who have had other diseases (high blood pressure, diabetes, malfunctioning heart valves, alcoholism, viruses) that damage the heart muscle, said Saxon. "These devices relieve symptoms such as shortness of breath, fatigue and fluid retention, and positively affect the lives of advanced heart failure patients who, at this time, have few alternatives," said De Marco.

Deprived of oxygen, patients with failing hearts often feel light-headed or faint and ultimately find it difficult to walk even a short distance. Only half of patients with mild to moderate heart failure survive for five years and only half of patients with severe failure survive for one year, she said, adding that, after medications have failed, their only option is to wait for a transplant. Because heart transplantation is a limited therapeutic option (due to the absence of organs) and technology is advancing at such a rapid rate, the new devices, manufactured by Indianapolis, Indiana-based Guidant Corporation, have enormous potential for the heart failure patient, De Marco said.

The multi-center clinical trial to test devices will enroll up to 2,200 patients in at least 80 medical centers across the United States and is expected to take three or four years to complete. Participants will be assigned randomly to one of three treatment groups:

Local patients participating in the trial are receiving care at the UCSF Cardiomyopathy and Arrythmia Research and Education (CARE) Center - the first U.S. center to provide the integrated services of heart failure specialists, arrhythmia specialists, and allied health care professionals. Founded by Saxon and De Marco, the approach combines basic clinical research, medical device and surgical therapies, prevention, and treatment, and serves as a prototype and central hub for similar sites being developed across the U.S.

The CARE center recently received a $1,000,000 grant from the Guidant Foundation, to maintain a national database of heart failure and arrhythmia research outcomes from up to 20 centers across the United States. The grant will also support the Center's efforts to train future generations of physicians who will care for heart failure patients.

Patients interested in enrolling in the trial should contact Kim Prouty, RN, UCSF research coordinator for heart failure and arrhythmia at 415-476-9218.
-end-
NOTE TO THE MEDIA: To set up interviews with Saxon and De Marco and/or patients who have had the device implanted and are experiencing a marked improvement in quality of life, please contact Maureen McInaney at 415-476-2557.

University of California - San Francisco

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.